Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

CRISPR Gene Editing Will Find Applications in Plastic and Reconstructive Surgery

By Wolters Kluwer Health | October 30, 2018

The CRISPR genome editing technique promises to be a “transformative leap” in genetic engineering and therapy, affecting almost every area of medicine. That includes plastic surgery, with potential advances ranging from prevention of craniofacial malformations, to therapeutic skin grafts, to new types of rejection-free transplants, according to a paper in the November issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

“CRISPR’s potential impact on treating human disease includes several areas important to the plastic surgeon such as oncology, wound healing, immunology, and craniofacial malformations,” comments ASPS Member Surgeon Eric Chien-Wei Liao, MD, PhD, Director of the Cleft and Craniofacial Program, Laurie and Mason Tenaglia MGH Research Scholar, Massachusetts General Hospital, Harvard Medical School. In a special regenerative medicine article, Dr. Liao and coauthors review the history and mechanisms of CRISPR genome editing, highlighting its potential uses and impact in plastic and reconstructive surgery.

CRISPR Has Implications for Congenital Malformations, Wound Healing, Transplantation and More

CRISPR – the abbreviation stands for “clustered regularly interspaced short palindromic repeats” – was discovered as an adaptive immune mechanism in bacteria. Before the development of CRISPR techniques, gene editing was labor intensive and limited to laboratories with advanced molecular biology tools.

“CRISPR gene editing is revolutionizing the potential of gene therapy due to its simplicity, specificity, efficiency, low cost, and versatility,” Dr. Liao and coauthors write. “Potential applications of CRISPR are numerous and will certainly impact plastic and reconstructive surgery.”

The authors discuss some key areas where CRSIPR has foreseeable implications for plastic surgery, including:

  • Craniofacial Malformations. Basic science studies using CRISPR techniques have already led to new insights into craniofacial developmental pathways. CRISPR enables quick identification of individual gene mutations, and may one day lead to the ability to correct mutations and prevent the development of cleft lip, cleft palate, and other congenital malformations.
  • Wound Healing and Tissue Repair. Gene therapy is a promising approach to enhancing wound and tissue healing. In addition to accelerated healing of skin wounds, CRISPR may lead to new approaches for repair and regeneration of bone, cartilage, nerve, and muscle.
  • Cell Therapy and Tissue Engineering. Genetic techniques may enable the creation or modification of the patient’s own (autologous) cells to graft or replace damaged tissues, stimulate cell development, or modulate immune functions. “[Techniques] of creating skin grafts with therapeutic potential would have widespread impact in reconstructive surgery,” Dr. Liao and coauthors write.
  • Flap Biology and Transplants. In addition to modifying tissue flaps, gene editing with CRISPR may make it possible to reprogram vascularized composite allotransplants – such as face or hand transplants – to promote tolerance and prevent rejection by the recipient’s immune system. Similar immune modulation approaches might also promote tolerance of tissues from animal donors (xenotransplantation).

Dr. Liao and colleagues emphasize that many challenges remain in realizing these and other clinical advances with CRISPR gene editing, including potential “off-target” effects, FDA regulation and high costs, and ethical issues related to genetic editing of human cells and tissues. The authors write, “The ASPS and its members should become stakeholders as well, and participate in future debates on the ethical use of CRISPR for the betterment of our patients.”


Filed Under: Genomics/Proteomics
Tagged With: CRISPR Gene Editing
 

Related Articles Read More >

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE